-
Acoustic Pharmaceutical CDK4/6 inhibitors were approved for bone marrow protection in clinical chemotherapy patients
Time of Update: 2021-03-10
According to insight database, G1 has launched seven clinical trials abroad for Trilaciclib, with adaptations including small cell lung cancer, colorectal cancer, breast cancer, etc.; from: Insight Database () At the 2019 ASCO conference, G1 published randomized, double-blind, multi-center Phase 2 study data for treated broad-term SCLC patients who were randomly treated with topological trilaciclib or placebo therapy, with a total of 91 patients randomized.
-
Two Indian drug companies, Esomerazole and Tekmos, have been recalled!
Time of Update: 2021-03-10
Indian drug companies that have recently been recalled in the U.S. are not the only ones in Sepra, and another FDA statement said that since last month, Bangalore, India-based Strides Pharmaceuticals inc.
-
In the face of biotech after the wave of people blessed and so on a group of traditional pharmaceutical companies how to "live" counter-attack?
Time of Update: 2021-03-10
02 Rohingya Pharmaceuticals: The first shot of innovation transformation On January 3, 2021, Rohingya Pharmaceuticals announced that its research and development of a class 1 digestive innovation drug - potassium ion competitive acid blocker (P-CAB) LXI-15028 was officially accepted by the CDE listing application, which is the second P-CAB products officially reported for production.
-
The State Drug Administration revised the instruction manual for quick-acting heart-saving pills, requiring warning signs to include "pregnant women banned"
Time of Update: 2021-03-10
In accordance with the revised requirements, quick-acting heart-saving pill instructions should include the prohibition of pregnant women, "adverse reactions" should increase nausea, vomiting, dry mouth, headache, dizziness, rash, itching, redness, fatigue, allergies and allergic reactions, "taboo" should be added "pregnant women disabled" and "allergic to this product and the ingredients contained in the disablement", "precautions" should increase the use of allergic physique.
-
Exposure Station: Shandong Provincial Drug Administration reported that 11 batches of drugs were not qualified
Time of Update: 2021-03-10
November 6, 2020, the Zhejiang Provincial Drug Administration issued the 2nd issue of Zhejiang Province drug quality spot check inspection notice notice, indicating that the labeling of the production enterprises as The first batch of Zhongqiang in Zhangzhou before Hu (production lot number: 180601) content determination does not meet the requirements.
-
Tianyu shares: subsidiary Ebershatan tablets obtained a drug registration certificate
Time of Update: 2021-03-10
treatment for primary hypertension and type 2 diabetic nephropathy, which combines hypertension, was first developed and marketed by Sanofi Pharmaceuticals of France under the name Aprovel.
-
The FDA officially released its annual report on new drugs in 2020
Time of Update: 2021-03-10
fda approved several approved drug expansion adaptations or patient groups last year, in addition to approving innovative therapies.
, for example, in December, the FDA approved Belysta (belimumab) extended adaptation for the treatment of active lupus nephritis (LN) adult patients undergoing standard therapies.
-
4 imported new drugs proposed breakthrough therapy 2 from Takeda Pharmaceuticals
Time of Update: 2021-03-10
From the CDE website Insight database, the drug has started 4 clinical projects in China, the developing indications include immunoploid reduction (Phase III clinical), severe muscle weakness (Phase II clinical), optic neurospinalitis (Phase I clinical) and diffuse goiter with hyperplatic hyperplus (approved clinical).
-
The clinical application for IL-23p19 antibody of Stone Pharmaceutical Group was approved by the FDA
Time of Update: 2021-03-10
addition, NBL-015, another all-human anti-Cludin 18.2 monoclonal antibody recently developed by the company, was approved by the FDA as an orphan drug for the treatment of pancreatic cancer.
: Sing Pharmaceutical Group's new drug NBL-012 has been approved for clinical trials in the United States.
-
Jianjin Pharmaceutical injection with hydrochloric acid benzodamostin by the State Drug Administration drug registration certificate
Time of Update: 2021-03-10
injection of benzodiaxine hydrochloride, an alkane agent primarily used for chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL), was first marketed in the United States in 2008 (trade name: TREANDA® ), the applicant is CEPHALON, the specification is 25mg/bottle, 100mg/bottle, of which 100mg specification of the original drug was approved in China in 2018, 25mg specification is only Zhengda Tianqing Pharmaceutical Group Co., Ltd. a generic drug listed.
-
Discussing the "previous life and present life" of jaundyl hydrochloride
Time of Update: 2021-03-10
On the one hand, the design and morphological analysis of microcosmic engineering have not only achieved remarkable results in the field of antibacterial, antiviral, anti-inflammatory, anti-tumor, anti-diabetic, and treatment of cardiovascular diseases in traditional pharmacological research.
-
Lilly Barrettini down to 1064 yuan down more than 73%!
Time of Update: 2021-03-10
Elamine is a tyrosine protein kinase (JAK) 1/2 inhibitor that is given orally once a day, far less than its daily dose compared to shangjie, the first oral drug of its kind already on the market in China.
-
New use of poison - A's cream, B's honey
Time of Update: 2021-03-09
It wasn't until 1998, when the New England Journal of Medicine reported on studies at memorial Sloan-Kettering Cancer Center and Cornell Medical School that As2O3 was treated for APL patients and was almost completely relieved, that the international medical community widely accepted the therapeutic effects of As2O3 on APL.
-
Several Kun technology refinancing three types of certificates and capital to accelerate the value of medical AI landing
Time of Update: 2021-03-09
"Digital heart" product family as an intelligent platform around the heart scene, its next 8 products have covered health screening, in-hospital accurate diagnosis, preoperative accurate assessment, out-of-hospital follow-up of the whole disease cycle, has been in public hospitals, private hospitals, regional medical service centers and other medical institutions at all levels of commercial use, a cumulative service of tens of millions of people.
-
Margenza significantly reduces the risk of disease progress/death and re-introduces medicine to China
Time of Update: 2021-03-09
It's worth noting that Margenza is the first HER2 targeted therapy to significantly improve progressive survival (PFS) in a head-to-head Phase 3 clinical trial compared to Roche's ace biologic agent Herceptin (Herceptin, generic name: trastuzumab, tratojutatin monoantigen), which is approved to market as a new treatment option for her2-positive metastasis breast cancer patients.
-
Sudden! The general manager of a multinational pharmaceutical company in China has left his appointment
Time of Update: 2021-03-09
Sammy Karam, Abbott's senior vice president and head of emerging markets for the pharmaceutical business, announced the news to employees that Mr Kim would leave Abbott to seek other career opportunities, with the last working day on March 5.
-
Selling 4.5 yuan of expired drugs The pharmacy was fined 100,000 yuan
Time of Update: 2021-03-09
In accordance with the relevant provisions of Article 117, paragraph 1, of the Drug Administration Law of the People's Republic of China, the Market Supervision Bureau of Yandu District confiscates expired Chinese medicine tablets and illegal income of the parties concerned, and punishes them with a fine of ten times the value of the goods (based on 10,000 yuan) and a fine of 100,000 yuan.
-
Giffeitini was "named" small molecules targeted drug anti-tumor to "change the day"?
Time of Update: 2021-03-09
Figure 2 Pharmaceutical segment composition in the field of anti-tumor drugs according to the PDB drug comprehensive database statistics (see Figure 3), in the small molecular targeting drug family, we found that imatinib, giffeitinib and ecstasy in 2016, cumulative sales reached 1,155 million yuan, accounting for 61.8% of the entire family at that time!
-
Clinical trials to develop a new crown for the treatment of severe diseases in the pharmaceutical industry have been officially launched in Brazil
Time of Update: 2021-03-09
The clinical trial of pruceline for the treatment of severe neo-crown patients is a multi-center, randomized, double-blind, placebo parallel-controlled study initiated by researchers to explore the effectiveness of psylone in patients with severe neo-coronary disease.
-
The first three total Yescartas were approved in Japan: treatment of relapsed/re treatable large B-cell lymphoma
Time of Update: 2021-03-09
In the Japan Phase 2 Open Label Single Arm Study, the efficacy and safety of 16 recurring or recurring large B-cell lymphomas (including DLBCL, PMBCL, tFL, HGBL) in Japanese patients treated with yescarta at the same dose as the ZUMA-1 study (2.0 x 10 x 6 square cells/kg).
